Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder - Intellia

Intellia shares rise after new Phase 3 lonvo-z data showed significant reductions in HAE attacks and reinforced its regulatory outlook.

Raccontata dabenzinga.com